PTC Therapeutics (PTCT) : During the past 4 weeks, traders have been relatively bearish on PTC Therapeutics (PTCT), hence the stock is down -19.22% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -16.8% relative to the S&P 500. The 4-week change in the price of the stock is -16.5% and the stock has fallen -16.85% in the past 1 week.
The stock has recorded a 20-day Moving Average of 14.11% and the 50-Day Moving Average is 17.27%. PTC Therapeutics, Inc. has dropped 19.54% during the last 3-month period . Year-to-Date the stock performance stands at -81.57%.
PTC Therapeutics (NASDAQ:PTCT): stock turned positive on Friday. Though the stock opened at $5.71, the bulls momentum made the stock top out at $6.14 level for the day. The stock recorded a low of $5.69 and closed the trading day at $5.97, in the green by 3.47%. The total traded volume for the day was 1,557,894. The stock had closed at $5.77 in the previous days trading.
PTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that target post-transcriptional control processes. The Companys internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. The Companys lead product, Translarna (ataluren), is used for the treatment of genetic disorders due to a nonsense mutation in ambulatory patients aged five years and older. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF).